We Are Developing Life-Changing Therapies Through the Use of Our Proprietary Technologies.
Advancing cell-based CAR T therapeutics targeting significant unmet need in B-cell non-Hodgkin lymphoma
- Significantly differentiated from current CAR T therapies
- Expect to leverage academic and development collaborations to advance preclinical development, access manufacturing suites, establish CMC and regulatory infrastructure, and cost and risk mitigation.
- Potential for Orphan Drug designation
XCART is a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Lymphomas. The XCART technology, developed by The Scripps Research Institute in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell Lymphomas by generating patient- and tumor-specific CAR T cells.
Next generation half-life extension platform for biologics
- Receiving royalties under license agreement with Takeda
- Potential to partner with additional pharmaceutical companies
PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. It uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. PolyXen has been demonstrated in human clinical trials to confer extended half-life to biotherapeutics such as recombinant human erythropoietin (rhEPO) and recombinant Factor VIII (rFVIII).
Xenetic is leveraging PolyXen by partnering with biotechnology and pharmaceutical companies. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.